Healthcare

Addiction Biotech Cannabis Genetics Healthcare Medical Devices Pharmaceutical Science Veterinary
News Release Digital Asset Direct

Classiq Transforms Quantum Computing with Qmod, The First High-Level Language for Quantum Programming

Classiq Technologies

Classiq today announced the general availability of Qmod (Quantum Modeling Language), the first high-level language (HLL) for quantum coding. Following successful pilot projects with enterprise partners, Qmod is now accessible to developers, researchers and enterprises worldwide and will transform quantum computing with its efficient, approachable method of programming. Qmod facilitates advanced quantum modeling and enables developers to describe quantum algorithms at a high level of abstraction. It supports unique quantum-computing concepts alongside conventional constructs found in high-level classical programming languages. This innovative approach allows developers to focus on the functional intent of their algorithms while Classiq’s powerful compiler and synthesis engine handle the intricate hardware-aware quantum implementation details. “To deliver a business or scientific value, quantum computing must be useful and accessible to scientists and engineers seeking to use quantum computing to solve real-world problems, which today it is not,” said Heather West, PhD, Research Manager, Quantum Computing at IDC. “Today, programming a quantum computer happens at the hardware level, making the technology only accessible to quantum physicists and other quantum specialists. As we begin to talk about quantum utility and near-term applications, abstraction-level application programming will become a necessity for wide-spread quantum adoption and usage.” Why The Qmod Language Is Different Declarative programming: Qmod’s declarative nature lets users define what their algorithm should achieve rather than how to achieve it; Classiq’s synthesis engine compiler optimizes for hardware and other constraints automatically. Flexibility and interoperability: Whether through native syntax, Python or graphical representation, Qmod descriptions are easily translatable and compatible across different formats and hardware. Industry-ready: Qmod is a tool for researchers and industry applications, providing robust scalable solutions for enterprise-grade quantum software development in an era of steadily growing qubit counts and the resulting coding complexity. “As we go further in building a complete quantum software stack, our groundbreaking Qmod language enables quantum experts to produce sophisticated programs while also allowing developers without a quantum background to innovate and solve complex problems across a variety of industry domains,” said Nir Minerbi, CEO and co-founder of Classiq. “By abstracting the complexities of quantum programming, Qmod delivers the ability to create and deploy dynamic quantum applications effortlessly. In some cases, it’ll use perhaps five lines of code instead of the traditional 100 lines of code. Like Java for the worldwide web or BASIC for PCs, Qmod is intended to open the gates to advanced quantum implementation.” Classiq’s platform ensures that quantum algorithms designed with Qmod can be seamlessly compiled for a broad range of hardware and simulation environments, as well as supporting seamless HPC integration. The platform's synthesis engine dynamically adapts implementations to different hardware configurations, allowing for rapid benchmarking and ensuring optimal implementations that make the very most of the available hardware. About Classiq Classiq Technologies, the leading quantum software company, provides an all-encompassing platform (IDE, compiler and OS) with a single point of entry into quantum computing, taking you from algorithm design to execution. The high-level descriptive quantum software development environment, tailored to all levels of developer proficiency, automates quantum programming. This ensures that a broad range of talents, including those with backgrounds in AI, ML and linear algebra, can harness quantum computing without requiring deep, specialized knowledge of quantum physics. Classiq democratizes access to quantum computing and equips its users to take full advantage of the quantum computing revolution, including access to a broad range of quantum hardware. Classiq’s core technology, algorithmic quantum circuit compilation, is engineered to power the quantum ecosystem of today and the future. Classiq works closely with quantum cloud providers and advanced computation hardware developers providing software for use with quantum computers, HPC, and quantum simulators. Backed by investors such as HPE, HSBC, Samsung, Intesa Sanpaolo and NTT, Classiq’s world-class team of scientists and engineers has distilled decades of quantum expertise into its groundbreaking quantum engine. Follow Classiq on LinkedIn, X (formerly Twitter) or YouTube, and visit the Slack community and https://www.classiq.io to learn more. Contact Details Rainier Communications Michelle Allard McMahon classiqPR@rainierco.com Company Website http://www.classiq.io/

July 23, 2024 08:00 AM Eastern Daylight Time

Image

Classiq and QuEra Announce Integration of Neutral-Atom Quantum Computers into Classiq Platform

Classiq Technologies

Classiq, the leader in quantum software development, and QuEra Computing, the leader in neutral-atom quantum computing, today announced a strategic collaboration to integrate QuEra’s cutting-edge neutral-atom quantum computers into the Classiq platform. This integration will enable customers to optimize a wide variety of quantum and hybrid quantum/classical algorithms for QuEra’s quantum computers, leveraging the unique capabilities of QuEra’s advanced quantum technology. With this collaboration, Classiq users will be able to exploit the distinctive features of QuEra’s neutral-atom quantum computers, such as the ability to simultaneously operate on multiple qubits and advanced qubit shuttling. Additionally, the integration provides access to Classiq’s extensive pre-written algorithmic blocks and allows customers to estimate the resources needed to run their algorithms. These capabilities enable the creation of highly resource-efficient algorithms with a large number of qubits and, in the future, for logical qubits as well. “Our partnership with QuEra represents a significant step forward in the quantum computing landscape,” said Nir Minerbi, CEO of Classiq. “By integrating QuEra’s neutral-atom technology into our platform, we are providing our users with unprecedented opportunities to enhance and optimize their quantum algorithms. This collaboration underscores our commitment to delivering the most versatile and powerful quantum computing solutions available.” “We are thrilled to collaborate with Classiq and bring the power of our neutral-atom quantum computers to a broader audience,” said Yuval Boger, Chief Commercial Officer of QuEra. “Classiq’s platform is renowned for its ease of use and flexibility, and by integrating our technology, we can help users unlock new potential and achieve groundbreaking results in their quantum computing projects.” The integration of QuEra’s quantum computers into the Classiq platform is expected to accelerate the development and deployment of quantum applications across various fields, including pharmaceuticals, finance, logistics and more. Customers who have purchased on-premises computers will be able to use the Classiq platform for the rapid development of quantum algorithms. This partnership highlights the ongoing commitment of both companies to drive innovation and make quantum computing more accessible and impactful. About Classiq Classiq Technologies, the leading quantum software company, provides an all-encompassing platform (IDE, compiler and OS) with a single point of entry into quantum computing, taking you from algorithm design to execution. The high-level descriptive quantum software development environment, tailored to all levels of developer proficiency, automates quantum programming. This ensures that a broad range of talents, including those with backgrounds in AI, ML and linear algebra, can harness quantum computing without requiring deep, specialized knowledge of quantum physics. Classiq democratizes access to quantum computing and equips its users to take full advantage of the quantum computing revolution, including access to a broad range of quantum hardware. Classiq’s core technology, algorithmic quantum circuit compilation, is engineered to power the quantum ecosystem of today and the future. Classiq works closely with quantum cloud providers and advanced computation hardware developers providing software for use with quantum computers, HPC, and quantum simulators. Backed by investors such as HPE, HSBC, Samsung, Intesa Sanpaolo and NTT, Classiq’s world-class team of scientists and engineers has distilled decades of quantum expertise into its groundbreaking quantum engine. Follow Classiq on LinkedIn, X (formerly Twitter) or YouTube, and visit the Slack community and https://www.classiq.io to learn more. About QuEra QuEra Computing is the leader in commercializing quantum computers using neutral atoms—widely recognized as a highly promising quantum modality. Based in Boston and built on pioneering research from nearby Harvard University and MIT, QuEra operates the world’s largest publicly accessible quantum computer, available over a major public cloud and for on-premises delivery. QuEra is developing large-scale, fault-tolerant quantum computers to tackle classically intractable problems, becoming the partner of choice in the quantum field. Simply put, QuEra is the best way to quantum. For more information, visit us at quera.com and follow us on X or LinkedIn. Contact Details Rainier Communications on behalf of Classiq Michelle Allard McMahon classiqPR@rainierco.com Merrill Freund on behalf of QuEra +1 415-577-8637 press@quera.com Company Website http://www.classiq.io/

July 23, 2024 08:00 AM Eastern Daylight Time

BestGrowthStocks.Com Issues Analysis on the Next Beneficiaries of the AI Revolution

SoundHound AI Inc.

NEW YORK, NY / NewsDirect / July 22nd, 2024 / Best Growth Stocks, a leading independent equity research and corporate access firm focused on finding and reporting on the best growth stocks utilizing exclusive ai-assisted research recently issued a comprehensive analysis of SoundHound AI, Inc. a pioneer in advanced voice-enabled AI and conversational intelligence technologies and a comprehensive analysis of the next beneficiaries of the AI revolution. SoundHound AI, Inc. (NASDAQ: SOUN) has garnered significant investor attention following multiple recent announcements that could prove to be significant catalysts for the AI company. Best Growth Stock's full report offers an analysis of SoundHound’s operations, potential upcoming catalysts, growth drivers, financials, share structure, chart, and more. Bonus content “The Next Beneficiaries of the AI Revolution” offers a comprehensive analysis of the next beneficiaries of the AI revolution, which ones stand to benefit near term, and stocks under $15/share to watch within each sector. Access this full analysis and bonus AI report with no obligation: https://bestgrowthstocks.com/soun-analysis/ Access this full analysis and bonus AI report with no obligation: https://bestgrowthstocks.com/soun-analysis/ About SoundHound AI SoundHound AI (Nasdaq: SOUN), a global leader in conversational intelligence, offers voice AI solutions that let businesses offer incredible conversational experiences to their customers. Built on proprietary technology, SoundHound’s voice AI delivers best-in-class speed and accuracy in numerous languages to product creators across automotive, TV, and IoT, and to customer service industries via groundbreaking AI-driven products like Smart Answering, Smart Ordering, and Dynamic Drive Thru, an AI-powered multimodal food ordering solution. Along with SoundHound Chat AI, a powerful voice assistant with integrated Generative AI, SoundHound powers millions of products and services, and processes billions of interactions each year for world class businesses. About Best Growth Stocks Best Growth Stocks is a leading independent equity research and corporate access firm focused on finding and reporting on the best growth stocks utilizing our exclusive ai-assisted research. BGS is also a financial news provider, focused on giving investors direct access to CEOs of promising, publicly-traded companies, and market experts. Our CEO interviews aim to answer the questions that rest on the minds of current and future shareholders. This is not to be construed as financial advice. Please consult with a licensed financial advisor before making any investment decisions. Media Contact Best Growth Stocks Senior Editor: Steve Macalbry Editor@BestGrowthStocks.com SOURCE: BestGrowthStocks.Com Contact Details Media Source LLC Steve Macalbry +1 989-274-7778 Editor@bestgrowthstocks.com

July 22, 2024 07:00 AM Eastern Daylight Time

Image

Tonix Pharmaceuticals Awarded potential 34 million dollar Contract with U.S. Department of Defence

Tonix Pharmaceuticals

Tonix Pharmaceuticals CEO Dr. Seth Lederman joined Steve Darling from Proactive to share exciting news about a significant achievement for the company. Tonix Pharmaceuticals has been awarded a potential contract worth up to $34 million over five years by the Defense Threat Reduction Agency (DTRA), an agency within the U.S. Department of Defense. This contract aims to develop small molecule broad-spectrum antiviral agents for the prevention or treatment of infections, thereby enhancing the medical readiness of military personnel in biological threat environments. Dr. Lederman explained that Tonix’s program will concentrate on the optimization and development of its TNX-4200 program. The goal is to develop an orally available CD45 antagonist with broad-spectrum efficacy against various viral families through extensive preclinical evaluation. The program is expected to establish essential physicochemical properties, pharmacokinetics, and safety attributes to support an Investigational New Drug (IND) submission, ultimately funding a first-in-human Phase 1 clinical study. The agreement with DTRA is a strategic move to address the DoD’s objective of protecting U.S. Joint Forces from potential biological weapon threats. The DoD announced in December 2022 that it aims to move beyond the traditional ‘one bug, one drug’ approach and is seeking broad-spectrum drugs, as predicting which viruses or how many may be deployed in a biological threat scenario is challenging. Dr. Lederman emphasized that the collaboration with DTRA underscores Tonix Pharmaceuticals' commitment to advancing medical readiness and protection for military personnel. By developing a broad-spectrum antiviral agent, Tonix aims to provide a versatile and robust solution to potential viral threats, enhancing the preparedness and resilience of the U.S. military in diverse and unpredictable biological threat environments. The TNX-4200 program’s focus on creating an effective, orally available antiviral agent highlights Tonix’s innovative approach to addressing complex medical challenges. The successful development of this broad-spectrum antiviral could significantly impact the way viral infections are managed in military and potentially civilian populations, offering a proactive measure against a wide array of viral threats. Tonix Pharmaceuticals continues to be at the forefront of medical innovation, dedicated to developing cutting-edge solutions that meet the evolving needs of the healthcare and defense sectors. The support from the DoD through this substantial contract is a testament to the potential and importance of Tonix’s TNX-4200 program in safeguarding the health and readiness of military personnel against biological threats. Contact Details Proactive Investors +1 604-688-8158 na-editorial@proactiveinvestors.com

July 19, 2024 12:48 PM Eastern Daylight Time

Video

News Release

ABVC BioPharma's CEO Discusses New Drug Development and AI Integration

ABVC BioPharma

After successfully completing Phase II clinical trials for their medication to treat Major Depressive Disorder, ABVC BioPharma Inc. and AiBtl BioPharma Inc. are now embarking on a groundbreaking clinical study focused on Depression in Cancer Patients. This new study will integrate AI-driven solutions to address the significant challenge of depression among cancer patients, a condition that often complicates treatment and adversely affects overall quality of life. Dr. Uttam Patil shared with Steve Darling from Proactive that the study aims to gain a deeper understanding of the prevalence and impact of depression in cancer patients. It will explore innovative therapeutic approaches by integrating real-time patient monitoring and enhanced patient analysis through an AI model. This advanced methodology is expected to increase the lead time for clinical trials, utilizing novel and sophisticated treatment protocols. The clinical study will be conducted at the renowned Cedars-Sinai Medical Center, involving cancer patients who experience depressive symptoms. By leveraging advanced AI technologies and employing cutting-edge diagnostic and therapeutic techniques, the study aims to monitor and treat depression in participants under meticulous medical supervision. Dr. Patil emphasized that the integration of AI-driven solutions in this clinical study represents a significant leap forward in the treatment of depression in cancer patients. The use of real-time patient monitoring and AI-based analysis is anticipated to provide valuable insights and improve patient outcomes, setting a new standard for clinical trials in this area. The collaboration between ABVC BioPharma and AiBtl BioPharma highlights their commitment to advancing healthcare through innovative solutions. This study is poised to make a substantial impact on the management of depression in cancer patients, offering hope for improved quality of life and better treatment outcomes. Through this pioneering study, ABVC BioPharma and AiBtl BioPharma are at the forefront of integrating technology with healthcare, paving the way for future advancements in the field. The companies are dedicated to utilizing AI to enhance patient care and accelerate the development of effective treatments for depression in cancer patients. Contact Details Proactive North America +1 604-688-8158 na-editorial@proactiveinvestors.com

July 18, 2024 10:31 AM Eastern Daylight Time

Video

Tonix Pharmaceuticals receives positive feedback from FDA on Tonmya™ for fibromyalgia management

Tonix Pharmaceuticals

Tonix Pharmaceuticals (NASDAQ:TNXP) CEO Dr Seth Lederman joined Steve Darling from Proactive to announce the receipt of formal minutes from a pre-New Drug Application (NDA) meeting with the US FDA regarding Tonmya sublingual tablets, which is aimed at managing fibromyalgia. This significant development marks a crucial step forward in the regulatory process for Tonmya™. During the meeting, both the company and the FDA concurred that the proposed data package is comprehensive and sufficient to support the NDA submission. Tonix Pharmaceuticals has reaffirmed its plan to submit the NDA for Tonmya to the FDA in the second half of 2024. If the submission proceeds as planned, it could pave the way for a potential FDA approval in the second half of 2025. Dr Lederman highlighted the promising potential of Tonmya to benefit fibromyalgia patients, a demographic that frequently expresses dissatisfaction with existing treatment options. Many patients currently resort to using off-label treatments, including addictive and detrimental opioids, due to the lack of effective alternatives. The positive outcomes from the pre-NDA meeting underscore the robustness and completeness of the data package that supports the registration of Tonmya for the management of fibromyalgia. Tonix Pharmaceuticals is optimistic about the impact that Tonmya could have on the fibromyalgia treatment landscape. The company's focus remains on advancing this promising therapy through the regulatory process and ultimately providing a new, effective option for patients struggling with this challenging condition. Contact Details Proactive Investors +1 604-688-8158 na-editorial@proactiveinvestors.com

July 18, 2024 10:20 AM Eastern Daylight Time

Briefly Bio launches with $1.2m funding to help scientists reproduce complex experiments

Briefly Bio

Science is in a reproducibility crisis. In preclinical research, it’s estimated that over 50% of efforts to reproduce experiments fail, costing the industry over $50bn each year. Solving this problem, techbio startup Briefly Bio has launched with software that makes lab work more reproducible by helping scientists capture and share their work clearly and consistently. With this launch, Briefly Bio has secured a $1.2m pre-seed funding round. It was led by Compound VC, with participation from NP Hard, Tiny VC and angel investors across tech and biotech. Biological experiments have become increasingly complex. With this growing complexity, details that are critical to our shared understanding are often undocumented and lost. This makes scientific collaboration inefficient: lab scientists struggle to reproduce and build on top of each other's experiments; data scientists do not have the necessary context to analyse the data produced in their labs; and automation teams lack all details to build robotic labs. Briefly Bio is tackling this, creating a shared language for experiments that is consistent across scientists, and clear for any collaborator to understand. Their software uses AI to convert existing experiment descriptions into this consistent format, while automatically filling in gaps and spotting errors. This helps capture the value of every experiment that is run, and enables scientists to learn from each other’s work. Briefly was founded by Dr Katya Putintseva, Harry Rickerby and Staffan Piledahl. They have varied backgrounds, through academia, tech, biotech and robotics. Before founding the company, the three worked together at drug discovery startup LabGenius, where they helped build its ML-driven antibody discovery platform. Harry Rickerby, CEO and co-founder at Briefly Bio, commented: “Scientific methods are a bit like software code, they are a set of instructions that define how an experiment should be run. The majority of this ‘code’ is incomplete, since writing up each experiment completely takes a huge amount of effort. Now, with LLMs, there’s a way to make these methods consistent without imposing on a scientists’ workflow. As Github helped software engineers collaborate and build on each other’s code, we think Briefly can help scientists and engineers do the same with their experiments.” With AI and high throughput experimentation, there is an opportunity for huge improvements in the efficiency of scientific discovery. Hundreds of billions of dollars are being invested through startups and big pharma to take advantage. To realise this potential, science needs more consistency and transparency in how these datasets are generated, since the value of any model is a product of the data it has been trained on. Briefly Bio is building this necessary layer of infrastructure to accelerate scientific discovery in biology. “This is a revolution in documenting lab experiments. It is the future of foolproof knowledge-sharing between scientists” said Dr Gena Nikitin, Founder of Miphic. While Dr Maria Anastasina, Wet Lab Head at the Evolutionary and Synthetic Biology Unit, OIST, added: “Briefly has become a core part of our lab's knowledge base and a great help to me in training researchers and lab management”. And Suparna Kumar, PhD student at Weill Cornell commented: “Briefly Bio has become an indispensable part of my lab routine because it helps me save so much time”. Rob Harkness, CTO of Biosero, added: “We're very excited by what Breifly.Bio can offer with their software tools. Inconsistent and incomplete data can compromise research, making it difficult to reproduce experiments and undermining trust in scientific results. Digitalising and automating laboratory operations can address this, but this effort faces challenges of inefficiency and high error rates, primarily due to the diverse formats in which workflows are presented. Briefly.bio addresses this by converting scientific protocols written in natural language into a common and consistent structured format. This facilitates much faster design and implementation of automated systems, ensuring all critical information is captured and utilized effectively. The result is a significant boost in workflow integration, efficiency, and data quality, all of which are crucial for generating reliable experimental results. This leads to more comprehensive and innovative solutions in lab automation that can only help accelerate scientific research.” Shelby Newsad, Investor at Compound, commented: “The crux of successful science lies in consistent and executable methods. Whereas most bio software companies focus on data and its analysis, Briefly goes upstream to the core problem space of reproducibility via protocols. For the first time in science history, this incentivizes scientists to share more of their previously tacit knowledge. The fact that Briefly-made methods can be built and collaborated upon creates unique potential for network effects from their software.” Briefly Bio is creating a future where scientists can stop reinventing the wheel – spending time and resources on experiments that they can’t reproduce. This will enable scientists to produce datasets that will quickly expand our understanding of biology. About Briefly Bio Briefly Bio is the tool to make lab work reproducible. It helps scientists capture, share their experiments clearly and consistently. Briefly is based in London, UK. For more information, visit https://briefly.bio. About Compound VC Compound is a research-centric, thesis-driven investment firm. We are a team of investors, researchers, and operators. We use our domain expertise, network, and prior experiences to help our founders solve previously unsolvable technical problems, communicate these breakthroughs to the world, and scale commercialization. Contact Details Briefly Bio Bilal Mahmood +44 7714 007257 b.mahmood@stockwoodstrategy.com Company Website https://briefly.bio/

July 17, 2024 08:00 AM Eastern Daylight Time

Image

Medicus Pharma CEO Dr. Raza Bokhari Announces Updated Phase 2 Clinical Protocol Submission to FDA

Medicus Pharma

Dr. Raza Bokhari, Executive Chairman and CEO of Medicus Pharma joined Steve Darling from Proactive to announce the submission of a comprehensive and updated Phase 2 Investigational New Drug clinical protocol to the United States Food and Drug Administration (FDA). This protocol aims to non-invasively treat basal cell carcinoma of the skin using micro-needle arrays containing doxorubicin, developed by Medicus Pharma’s wholly owned portfolio company, Skinject, Inc. The submission features significant updates to the clinical protocol, including enhancements to the supporting Chemistry, Manufacturing, and Controls (CMC), along with detailed stability and sterility information. Furthermore, it addresses the clinical non-hold comments previously received from the FDA, ensuring a robust and thorough response to regulatory feedback. Dr. Bokhari shared with Proactive that the revised Phase 2 clinical protocol incorporates innovative elements such as artificial intelligence and confocal microscopy as supplementary endpoints at one of the clinical sites. These advanced technologies are expected to provide deeper insights and improved accuracy in the clinical outcomes. Medicus Pharma believes that this updated protocol is well-positioned to receive FDA approval, paving the way for the commencement of participant randomization potentially before the end of this quarter. This milestone underscores the company’s commitment to advancing innovative treatments for skin cancer and improving patient outcomes through cutting-edge technology and rigorous clinical research. Contact Details Proactive North America +1 604-688-8158 NA-editorial@proactiveinvestors.com

July 16, 2024 11:51 AM Eastern Daylight Time

Video

University Compounding Pharmacy Announces Rebrand to MediVera Compounding Pharmacy™

MediVera

University Compounding Pharmacy, a leader in personalized medicine since 1999, today announced it is rebranding as MediVera Compounding Pharmacy™. The rebrand comes at a time when the company is growing strongly due to the introduction of new product offerings, nationwide expansion, and the successful differentiation of its quality products and services. Despite the name change, the company’s ownership and passionate team remain the same, ensuring continuity in the high-level service and exceptional care that healthcare providers and patients have relied on for more than two decades. Over the past few years, the company has seen its revenue grow substantially. New product offerings, nationwide expansion, and strong market positioning through differentiated quality products and services, such as the Impressed Advantage program, have enabled the company to double its revenue from 2022 to 2023. Growth is anticipated to accelerate this year, with the company expecting to double revenue year-over-year once again. “Differentiation is and will continue to be an important growth driver for our company. With the Impressed Advantage customer service program, we are making the prescription process easier, faster, and more convenient for both doctors and their patients,” said Bradley McCloskey, PharmD, CEO. “As we continue to launch more product offerings and expand into more states within the next few months, 2024 is poised to become a year of strong growth as we expand our footprint into 14 additional states.” For more information about MediVera Compounding Pharmacy and its services, please visit mediverarx.com or contact Laurie Malseed, Marketing Specialist, at laurie@mediverarx.com or 937-242-0430. About MediVera Since its inception in 1999, MediVera Compounding Pharmacy™ (formerly University Compounding Pharmacy) has been dedicated to providing personalized medicine. With a focus on quality and innovation, MediVera Compounding Pharmacy™ continues to set industry standards, offering tailored solutions to meet the unique needs of healthcare providers and patients. MediVera Compounding Pharmacy™ is currently licensed in and ships to the following 33 states: AZ, CN, CO, DE, FL, GA, IA, ID, IL, IN, KY, MA, MD, ME, MI, MN, MO, MT, NC, NH, NJ, NY, OH, PA, RI, SC, SD, TN, VA, VT, WA, WI, WY. Contact Details MediVera Compounding Pharmacy Laurie Malseed +1 937-242-0430 laurie@mediverarx.com

July 16, 2024 09:00 AM Eastern Daylight Time

1 2 3 4 5 ... 175

Back